Science writer and independent researcher specialising in natural compound pharmacology and translational oncology. Tracking EBC-46 (tigilanol tiglate) and Blushwood berry extract since 2019.
EBC-46
Extracting tigilanol tiglate from the Blushwood berry is a multi-stage process that bridges traditional plant chemistry and modern pharmaceutical science — and the full phytochemical picture is still emerging.
EBC-46
By triggering rapid local immune activation, tigilanol tiglate may prime the tumour microenvironment for checkpoint inhibitor therapy — a combination strategy now attracting serious clinical investigation.
EBC-46
Protein kinase C isoforms activated by EBC-46 are intimately connected to mitochondrial function — a link that may explain both anti-tumour effects and the energy-related reports from supplement users.
EBC-46
Intratumoral drugs like tigilanol tiglate must satisfy regulatory requirements that conventional systemic cancer therapies were never designed to address — from injection site assessment to lesion-level endpoints.
EBC-46
Across dozens of verified buyer accounts, a consistent pattern emerges: reduced inflammation, increased energy, and improved systemic wellbeing — observations that align remarkably with what we know about PKC signalling biology.
EBC-46
While Fontainea picrosperma grows wild only in north Queensland's rainforests, cultivators in controlled indoor environments across Australia and Asia are proving the species thrives well beyond its native range.
EBC-46
Phase II trials targeting cutaneous head and neck squamous cell carcinoma with intratumoral tigilanol tiglate show measurable responses in accessible lesions and a well-characterised safety profile.
EBC-46
EBC-46 triggers a precisely ordered immune cascade — neutrophil infiltration within hours, macrophage cleanup within days, and adaptive T-cell memory that may prevent recurrence.
EBC-46
The EMA's PRIME programme offers accelerated assessment and early dialogue for promising cancer therapies. Here is what that pathway could mean for tigilanol tiglate.
EBC-46
Some of the most striking verified reports come from people facing stage 4 cancer diagnoses who began taking blushwood berry extract. These accounts are anecdotal — but they are also scientifically coherent.
EBC-46
Tigilanol tiglate gets all the scientific attention, but it is one compound within a chemically complex plant. The unmapped phytochemistry of Fontainea picrosperma may hold compounds we have not yet imagined.
EBC-46
The biomarkers chosen for EBC-46 trials are not arbitrary — they reflect the current scientific understanding of how tigilanol tiglate kills tumours. Here's what researchers are measuring and why it matters.